Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents

Medicinal Research Reviews

Volumn 24, Issue 5, 2004, Pages 662-684

  Matter, Hans ^a   Kotsonis, Peter ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

H4Bip binding site; Inhibitor; Nitric oxide synthase; NOS; Selectivity; Structure activity relationship

Indexed keywords

CALCIUM ION; CLOTRIMIDAZOLE; CYTOCHROME P450 REDUCTASE; DIHYDROISOQUINOLINE; DIHYDROPYRIDIN 2(1H) IMINE; DIHYDROPYRIDINE DERIVATIVE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FLAVINE ADENINE NUCLEOTIDE; GW 273629; HEME; HYDROGEN PEROXIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOQUINOLINE DERIVATIVE; MICONAZOLE; N METHYL DEXTRO ASPARTIC ACID; N(G) METHYLARGININE; N(G) NITROARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PTERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; TETRAHYDROBIOPTERIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; W 1400;

AMINO ACID SEQUENCE; BINDING AFFINITY; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG BINDING SITE; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITOR INTERACTION; HUMAN; INFLAMMATION; INHIBITION KINETICS; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; NERVE DEGENERATION; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE PROPERTY RELATION; REVIEW; SEPSIS; STROKE;

ANIMALS; ARGININE; BINDING SITES; BIOPTERIN; BRAIN ISCHEMIA; ENZYME INHIBITORS; HUMANS; INFLAMMATION; ISOENZYMES; NEURODEGENERATIVE DISEASES; NITRIC OXIDE SYNTHASE; PROTEIN CONFORMATION; PTERIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SEPSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3843057862     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20005     Document Type: Review

References (153)

1. Griffith OW, Gross SS. Inhibitors of nitric oxide synthases. In: Feelisch M, Stamler JS, editors. Methods in nitric oxide research. New York: John Wiley & Sons; 1996. pp 187-208.
2. Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol 1999;39:191-220.
3. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function, and inhibition. Biochem J 2001;357:593-615.
4. Schmidt HHHW, Nau H, Wittfoth W, Gerlach J, Prescher K-E, Klein MM, Niroomand F, Böhme E. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988;154:213-216.
5. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
6. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: The basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM, editor. Vasodilation: Vascular smooth muscle, peptides, autonomic nerves, and endothelium. New York: Raven; 1988. pp 401-414.
7. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
8. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
9. Stuehr DJ, Griffith OW. Mammalian nitric oxide synthases. In: Meister A, editor. Advances in enzymology and related areas of molecular biology, Vol. 65. New York: John Wiley & Sons; 1992. pp 287-346.
10. Schmidt HHHW, Walter U. NO at work. Cell 1994;78:919-925.
11. Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268:12231-12234.
12. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase: A calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682-685.
13. Crane BR, Arvai AS, Gachhui R, Wu C, Ghosh DK, Getzoff ED, Stuehr DJ, Tainer JA. The structure of nitric oxide synthase oxygenase domain and inhibitor complexes. Science 1997;278:425-431.
14. Raman CS, Li H, Martásek P, Král V, Masters BSS, Poulos TL. Crystal structure of constitutive nitric oxide synthase: A paradigm for pterin function involving a novel metal center. Cell 1998;95:939-950.
15. Sono M, Roach MP, Coulter ED, Dawson JH. Heme-containing oxygenases. Chem Rev 1996;96:2841-2888.
16. Förstermann U, Pollock JS, Schmidt HHHW, Heller M, Murad F. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:1788-1792.
17. Huang PL, Huang Z, Mashimo H, Bloch KD, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-242.
18. Shesely EG, Maeda N, Kim H-S, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996;93:13176-13181.
19. Moncada S, Palmer RM, Higgs EA. Relationship between prostacyclin and nitric oxide in the thrombotic process. Thromb Res Suppl 1990;11:3-13.
20. Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: Implications for synaptic plasticity. Proc Natl Acad Sci USA 1994;91:4214-4218.
21. Burnett AL, Lowenstein CJ, Bredt DS, Cang K, Snyder SH. Nitric oxide: A physiologic mediator of penile erection. Science 1992;257:401-403.
22. Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM, Snyder SH. Behavioral abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995;378:383-386.
23. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350.
24. Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol 1999;6:233-242.
25. Wang J, Stuehr DJ, Ikeda Saito M, Rousseau DL. Heme coordination and structure of the catalytic site in nitric oxide synthase. J Biol Chem 1993;268:22255-22258.
26. McMillan K, Masters BS. Prokaryotic expression of the heme- and flavin-binding domains of rat neuronal nitric oxide synthase as distinct polypeptides: Identification of the heme-binding proximal thiolate ligand as cysteine-415. Biochemistry 1995;34:3686-3693.
27. Cubberley RR, Alderton WK, Boyhan A, Charles IG, Lowe PN, Old RW. Cysteine-200 of human inducible nitric oxide synthase is essential for dimerization of heme domains and for binding of heme, nitroarginine, and tetrahydrobiopterin. Biochem J 1997;323:141-146.
28. Abu Soud HM, Stuehr DJ. Nitric oxide synthases reveal a role for calmodulin in controlling electron transfer. Proc Natl Acad Sci USA 1993;90:10769-10772.
29. G-hydroxyarginine is not relevant to the mechanism. J Am Chem Soc 2001;123:2674-2676.
30. Fedorov R, Ghosh DK, Schlichting I. Crystal structures of cyanide complexes of P450cam and the oxygenase domain of inducible nitric oxide synthase - Structural models of the short lived oxygen complexs. Arch Biochem Biophys 2003;409:25-31.
31. Schlichting I, Berendsen J, Chu K, Stock AM, Maves SA, Benson DE, Sweet RM, Ringe D, Petsko GA, Sligar SG. The catalytic pathway of cytochrome P450cam at atomic resolution. Science 2000;287:1615-1622.
32. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992;268:14781-14787.
33. Vasquez-Vivar J, Kayanaraman B, Martásek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. J Proc Natl Acad Sci USA 1998;95:9220-9225.
34. Kotsonis P, Frey A, Fröhlich LG, Hofmann H, Reif A, Wink DA, Feelisch M, Schmidt HHHW. Autoinhibition of neuronal nitric oxide synthase: Distinct effects of reactive nitrogen and oxygen species on enzyme activity. Biochem J 1999;340:745-752.
35. Heinzel B, John M, Klatt P, Böhme E, Mayer B. Calcium/calmodulin- dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 1992;281:627-630.
36. Vallance P, Leiper J. Blocking NO synthesis: How, where, and why? Nat Rev Drug Disc 2002;939-950.
37. Yoshida T, Limmroth V, Irikura K, Moskowitz MA. The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. J Cereb Blood Flow Metab 1994;14:924-929.
38. Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischaemia in mice deficient in neuronal nitric oxide synthase. Science 1994;265:1883-1885.
39. Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996;16:981-987.
40. Brouillet E, Beal MF. MDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 1993;4:387-390.
41. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU. MK-801 prevents MPTP-induced Parkinsonism, in primates. J Neurochem 1992;59:733-739.
42. Przedborski S, Jackson Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996;93:4565-4571.
43. Akama KT, Albanese C, Pestell RG, Van Eldik LJ. Amyloid β-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc Natl Acad Sci USA 1998;95:5795-5800.
44. Vodovotz Y, Lucia MS, Flanders KC, Chesler L, Xie QQ, Smith WW, Weidner J, Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996;184:1425-1433.
45. Vallance P, Charles I. Nitric oxide in sepsis: Of mice and men. Sepsis 1998;1:93-100.
46. Wray G, Thiemermann C. Nitric oxide in sepsis. Nitric Oxide Infect 1999;265-280.
47. Kengatharan KM, DeKimpe SJ, Thiemermann C. Role of nitric oxide in the circulatory failure and organ injury in a rodent model of gram-positive shock. Br J Pharmacol 1996;119:1411-1421.
48. Goode HF, Howdle PD, Walker BE, Webster NR. Nitric oxide synthase activity is increased in patients with sepsis syndrome. Clin Sci 1995;88:131-133.
49. Wong HR, Carcillo JA, Burckart G, Shah N, Janosky JE. Increased serum nitrite and nitrate concentrations in children with the sepsis syndrome. Crit Care Med 1995;23:835-842.
50. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-411.
51. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie QW, Sokol K, Hutchinson N. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81:641-650.
52. Petros A, Bennett D, Vallance P. Effects of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-1558.
53. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-39.
54. Guntupalli K, Grover R, Jeffs R, Colice G, Watson D, Vincent JL. Intensive Care Med 1995;21:S21.
55. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. Intensive Care Med 1995;21:S20.
56. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci USA 1994;91:2046-2050.
57. Luo ZD, Cizkova D. The role of nitric oxide in nociception. Curr Rev Pain 2000;4:459-466.
58. Saban MR, Nguyen NB, Hammond TG, Saban R. Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. Am J Pathol 2002;160:2095-2110.
59. van't Hof RJ, Ralston SH. Nitric oxide and bone. Immunology 2001;103:255-261.
60. Ialenti A, Ianaro A, Monada S, Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 1992;211:177-182.
61. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992;51:1219-1222.
62. Marletta MA. Approaches toward selective inhibition of nitric oxide synthase. J Med Chem 1994;37:1899-1907.
63. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 1990;101:746-752.
64. Olken NM, Marletta MA. N-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry 1993;32:9677-9685.
65. G-methylarginine hydrochloride in patients with septic shock. Clin Pharmacol Ther 1999;65:1-9.
66. Vallance O, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
67. Furfine ES, Harmon MF, Paith JE, Garvey EP. Selective inhibition of constitutive nitric oxide synthase by NO-nitroarginine. Biochemistry 1993;32:8512-8517.
68. δ-iminoethyl-L-omithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells. Br J Pharmacol 1991;102:234-238.
69. ω-nitroarginine and -phenylalanine containing dipeptides and dipeptide esters. J Med Chem 1997;40:2813-2817.
70. ω-nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase. J Med Chem 1999;42:3147-3153.
71. Hah J-M, Roman LJ, Martásek P, Silverman RB. Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoalkyl]aminopentyl)-N′- nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. J Med Chem 2001;44:2667-2670.
72. Hah J-M, Martásek P, Roman LJ, Silverman RB. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. J Med Chem 2003;46:1661-1669.
73. Garvey EP, Oplinger JA, Furfine ES, Kiff RJ, Laszlo F, Whittle BJR, Knowles RG. 1400 W is a slow, tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J Biol Chem 1997;272:4959-4963.
74. Parmentier S, Bohme GA, Lerouet D, Damour D, Stutzmann JM, Margaill I, Plotkine M. Selective inhibition of inducible nitric oxide synthase prevents ischemic brain injury. Br J Pharmacol 1999;127:546-552.
75. Wray GM, Millar CG, Hinds CJ, Thiemermann, C. Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. Shock 1998;9:329-335.
76. Evans SM, Whittle BJ. Interactive roles of superoxide and inducible nitric oxide synthase in rat intestinal injury provoked by non-steroidal anti-inflammatory drugs. Eur J Pharmacol 2001;429:287-296.
77. Narayanan K, Spack L, McMillan K, Kilbourn RG, Hayward MA, Masters BSS, Griffith OW. S-alkyl-L-thiocitrullines. J Biol Chem 1995;270:11103-11110.
78. Pollock JS, Förstermann U, Mitchell JA, Warner TD, Schmidt HHHW, Nakane M, Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:10480-10484.
79. Collins JL, Shearer BG, Oplinger JA, Lee S, Garvey EP, Salter M, Duffy C, Burnette TC, Furfine ES. N-phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: Structure-activity studies and demonstration of in vivo activity. J Med Chem 1998;41:2858-2871.
80. Lowe JA III, Qian W, Volkmann RA, Heck S, Nowakowski J, Nelson R, Nolan C, Liston D, Ward K, Zorn S, Johnson C, Vanase M, Faraci WS, Verdries KA, Baxter J, Doran S, Sanders M, Ashton M, Whittle P, Stefaniak M. A new class of selective and potent inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett 1999;9:2569-2572.
81. Beaton H, Hamley P, Nicholls DJ, Tinker AC, Wallace AV. 3,4-Dihydro-1-isoquinolinamines: A novel class of nitric oxide synthase inhibitors with a wide range of isoform selectivity and potency. Bioorg Med Chem Lett 2001;11:1023-1026.
82. Tinker AC, Beaton HG, Boughton-Smith N, Cook TR, Cooper SL, Fraser-Rae L, Hallam K, Hamley P, McInally T, Nicholls DJ, Pimm AD, Wallace AV. 1,2-Dihydro-4-quinazolinamines: Potent, highly selective inhibitors of inducible nitric oxide synthase which show antiinflammatory activity in vivo. J Med Chem 2003;46:913-916.
83. 2H-azepin-2-imines. Bioorg Med Chem 2003;11:689-702.
84. Kawanaka Y, Kobayashi K, Kusuda S, Tatsumi T, Murota M, Nishiyama T, Hisaichi K, Fujii A, Hirai K, Naka M, Komeno M, Odagaki Y, Nakai H, Toda M. Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Identification of 2-azabicyclo[4.1.0]heptan-3-imines. Bioorg Med Chem 2003;11:1723-1743.
85. Kawanaka Y, Kobayashi K, Kusuda S, Tatsumi T, Murota M, Nishiyama T, Hisaichi K, Fujii A, Hirai K, Naka M, Komeno M, Nakai H, Toda M. Design and synthesis of inhibitors of inducible nitric oxide synthase. Discovery of a new chemical lead with potential for oral bioavailability. Eur J Med Chem 2003;38:277-288.
86. Fujisawa Pharm Co. Ltd., 1997. WO9702254.
87. Takeda Chem Ind Ltd., 1996. EP-0737671-A.
88. MacDonald JE, Shakespeare WC, Murray RJ, Matz JR. 1996. Astra AB, Patent WO9601817.
89. MacDonald JE. 1996. Astra AB, Patent WO0624588.
90. Kato K, Miki S, Naruo K-I, Takahashi H. 1996. Chem Ind Ltd., Patent EP-0737671-A.
91. Chabin RM, McCauley E, Calaycay JR, Kelly TM, MacNaul KL, Wolfe GC, Hutchinson NI, Madhusudanaraju S, Schmidt JA, Kozarich JW, Wong KK. Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole. Biochemistry 1996;35:9567-9575.
92. Mayer B, Klatt P, Werner ER, Schmidt K. Molecular mechanisms of inhibition of porcine brain nitric oxide synthase by the antinociceptive drug 7-nitro-indazole. Neuropharmacol 1994;33:1253-1259.
93. McMillan K, Adler M, Auld DS, Baldwin JJ, Blasko E, Browne LJ, Chelsky D, Davey D, Dolle RE, Eagen KA, Erikson S, Feldman RI, Glaser CB, Mallari C, Morrissey MM, Ohlmeyer MH, Pan G, Parkinson JF, Phillips GB, Plokoff MA, Sigal NH, Vergona R, Whitlow M, Young TA, Devlin JJ. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci USA 2000;97:1506-1511.
94. Blasko E, Glaser CB, Devlin JJ, Xia W, Feldman RI, Polokoff MA, Phillips GB, Whitlow M, Auld DS, McMillan K, Ghosh S, Stuehr DJ, Parkinson JF. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J Biol Chem 2002;277:295-302.
95. Habisch H-J, Gorren ACF, Liang H, Venema RC, Parkinson JF, Schmidt K, Mayer B. Pharmacological interference with dimerization of human neuronal nitric-oxide synthase expressed in adenovirus-infected DLD-1 cells. Mol Pharmacol 2003;63:682-689.
96. Gorren ACF, Mayer B. Tetrahydrobiopterin in nitric oxide synthesis: A novel biological role for pteridines. Curr Drug Metab 2002;3:133-157.
97. Bec N, Gorren ACF, Voelker C, Mayer B, Lange R. Reaction of neuronal nitric-oxide synthase with oxygen at low temperature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem 1998;273:13502-13508.
98. Bömmel HM, Reif A, Fröhlich LG, Frey A, Hofmann H, Marecak DM, Groehn V, Kotsonis P, La M, Köster S, Meinecke M, Bernhardt M, Weeger M, Ghisla S, Prestwich GD, Pfleiderer W, Schmidt HHHW. Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase. J Biol Chem 1998;273:33142-33149.
99. Reif A, Fröhlich LG, Kotsonis P, Frey A, Bömmel HM, Wink DA, Pfleiderer W, Schmidt HHHW. Tetrahydrobiopterin inhibits monomerization and is consumed during catalysis in neuronal NO synthase. J Biol Chem 1999;274:24921-24929.
100. Kotsonis P, Fröhlich LG, Shutenko ZV, Horejsi R, Pfleiderer W, Schmidt HHHW. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem J 2000;346:767-776.
101. McMillan K, Masters BS. Optical difference spectrophotometry as a probe of rat brain nitric oxide synthase heme-substrate interaction. Biochemistry 1993;32:9875-9880.
102. Klatt P, Schmidt K, Lehner D, Glatter O, Bächinger HP, Mayer B. Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and L-arginine in the formation of an SDS-resistant dimer. EMBO J 1995;14:3687-3695.
103. Klatt P, Schmidt M, Leopold E, Schmidt K, Werner ER, Mayer B. The pteridine binding site of brain nitric oxide synthase. Tetrahydrobiopterin binding kinetics, specificity, and allosteric interaction with the substrate domain. J Biol Chem 1994;269:13861-13866.
104. Kwon NS, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989;264:20496-20501.
105. Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 1989;264:19654-19658.
106. Wemer ER, Pitters E, Schmidt K, Wemer-Felmayer G, Mayer B. Identification of the 4-amino analog of tetrahydrobiopterin as a dihydropteridine reductase inhibitor and a potent pteridine antagonist of rat neuronal nitric oxide synthase. Biochem J 1996;320:193-196.
107. Fröhlich LG, Kotsonis P, Traub H, Taghavi-Moghadam S, Al-Masoudi N, Hofmann H, Strobel H, Matter H, Pfleiderer W, Schmidt HHHW. Inhibition of neuronal nitric oxide synthase by 4-amino pteridine derivatives: Structure-activity relationship of antagonists of (6R)-5,6,7,8- tetrahydrobiopterin cofactor. J Med Chem 1999;42:4108-4121.
108. Wemer ER, Schmidt HHHW. Nitric-oxide-synthase inhibitors II. Pterin antagonists/anti-pterins. Handbook Exp Pharmacol 2000;143:137-158.
109. Kotsonis P, Fröhlich LG, Raman CS, Berg M, Gerwig R, Groehn V, Kang Y, Al-Masoudi N, Taghavi-Moghadam S, Mohr D, Münch U, Schnabel J, Poulos TL, Strobel H, Masters BSS, Matter H, Pfleiderer W, Schmidt HHHW. Development of novel 4-oxo pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin in neuronal nitric oxide synthase. J Biol Chem 2001;276:49133-49141.
110. Pfeiffer S, Gorren ACF, Pitter E, Schmidt K, Wemer ER, Mayer B. Allosteric modulation of rat brain nitric oxide synthase by the pterin-site enzyme inhibitor 4-aminotetrahydrobiopterin. Biochem J 1997;328:349-352.
111. Werner ER, Werner-Felmayer G. Biopterin analogues: Novel nitric oxide synthase inhibitors with immunosuppressive action. Curr Drug Metabol 2002;3:119-121.
112. Raman CS, Martásek P, Masters BSS. Structural themes determining function in nitric oxide synthases. In: Kadish KM, Smith KM, Guilard R, editors. The porphyrin handbook, Vol. 4, biochemistry, and binding: Activation of small molecules. London: Academic Press; 2000. pp 293-339.
113. Crane BR, Arvai AS, Ghosh DK, Wu C, Getzoff ED, Stuehr DJ, Tainer JA. Structure of nitric oxide synthase oxygenase dimer with pterin and substrate. Science 1998;279:2121-2126.
114. Li H, Shimizu H, Flinspach M, Jamal J, Yang W, Xian W, Cai T, Wen EZ, Jia Q, Wang PG, Poulos TL. The novel binding mode of N-alkyl-N′- hydroxyguanidine to neuronal nitric oxide synthase provides mechanistic insights into NO biosynthesis. Biochemistry 2002;41:13868-13875.
115. Werner-Felmayer G, Gross SS. Analysis of tetrahydrobiopterin and its role in nitric oxide synthesis. In: Feelisch M, Stamler JS, editors. Methods in nitric oxide research. New York: John Wiley & Sons; 1996. pp 271-299.
116. Gorren ACF, List BM, Schrammel A, Pitters E, Hemmens B, Wemer E, Schmidt K, Mayer B. Tetrahydrobiopterin-free neuronal nitric oxide synthase: Evidence for two identical highly anticooperative pteridine binding sites. Biochemistry 1996;35:16735-16745.
117. Mayer B, Wu C-Q, Gorren ACF, Pfeiffer S, Schmidt K, Clark P, Stuehr DJ, Werner ER. Tetrahydrobiopterin binding to macrophage inducible nitric oxide synthase: Heme spin shift and dimer stabilization by the potent pterin antagonist 4-amino-tetrahydrobiopterin. Biochemistry 1997;36:8422-8427.
118. Klatt P, Schmidt K, Lehner D, Glatter O, Bachinger HP, Mayer B. Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and L-arginine in the formation of an SDS-resistant dimer. EMBO J 1995;14:3687-3695.
119. Li H, Raman CS, Glaser CB, Blasko E, Young TA, Parkinson JF, Whitlow M, Poulos TL. Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase. Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem 1999;274:21276-21284.
120. RCSB Protein Data Bank from the Research Collaboratory for Structural Bioinformatics. http:// www.rcsb.org/pdb/index.html.
121. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res 2000;28:235-242.
122. Presta A, Siddhanta U, Wu C-Q, Sennequier N, Huang L-X, Abu-Soud HM, Erzurum S, Stuehr DJ. Comparative functioning of dihydro- and tetrahydro-pterins in supporting electron transfer, catalysis, and subunit dimerization in inducible nitric oxide synthase. Biochemistry 1998;37:298-310.
123. Samanta U, Pal D, Chakrabarti P. Environment of tryptophan side chains in proteins. Proteins 2000;38:288-300.
124. Cho HJ, Martin E, Xie Q-W, Sassa S, Nathan C. Inducible nitric oxide synthase: Identification of amino acid residues essential for dimerization and binding of tetrahydrobiopterin. Proc Natl Acad USA 1995;92:11514-11518.
125. Ghosh S, Wolan D, Adak S, Crane BR, Kwon NS, Tainer JA, Getzoff ED, Stuehr DJ. Mutational analysis of the tetrahydrobiopterin-binding site in inducible nitric-oxide synthase. J Biol Chem 1999;274:24100-24112.
126. Aoyagi M, Arvai AS, Ghosh S, Stuehr DJ, Tainer JA, Getzoff ED. Structures of tetrahydrobiopterin binding-site mutants of inducible nitric oxide synthase oxygenase dimer and implicated roles of Trp457. Biochemistry 2001;40:12826-12832.
127. Rosenfeld RJ, Garcin ED, Panda K, Andersson G, Aberg A, Wallace AV, Morris GM, Olson AJ, Stuehr DJ, Tainer JA, Getzoff ED. Conformational changes in nitric oxide synthases induced by chlorzoxazone and nitroindazoles: Crystallographic and computational analyses of inhibitor potency. Biochemistry 2002;41:13915-13925.
128. Panda K, Rosenfeld RJ, Ghosh S, Meade AL, Getzoff ED, Stuehr DJ. Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III. J Biol Chem 2002;277:31020-31030.
129. Goodwill KE, Sabatier C, Stevens RC. Crystal structure of tyrosine hydroxylase with bound cofactor analog and iron at 2.3 Å resolution: Self-hydroxylation of Phe300 and the pterin-binding site. Biochemistry 1998;37:13437-13445.
130. Cronk JD, Endrizzi JA, Alber TA. High-resolution structures of the bifunctional enzyme and transcriptional coactivator DCoH and its complex with a product analog. Protein Sci 1996;5:1963-1972.
131. Varughese KI, Skinner MM, Whiteley JM, Matthews DA, Xuong NH. Crystal structure of rat liver dihydropteridine reductase. Proc Natl Acad Sci USA 1992;89:6080-6084.
132. Kaufman S. Tyrosine hydroxylase. Adv Enzymol 1995;70:103-220.
133. Dix T, Benkovic SJ. Mechanism of oxygen activation by pteridine-dependent monooxygenases. Acc Chem Res 1988;21:101-107.
134. Rodriguez-Crespo I, Nishida CR, Knudsen GM, Ortiz de Montellano PRJ. Mutation of the five conserved histidines in the endothelial nitric-oxide synthase hemoprotein domain. No evidence for a non-heme metal requirement for catalysis. Biol Chem 1999;274:21617-21624.
135. Yan X, Hollis T, Svinth M, Day P, Monzingo AF, Milne GWA, Robertus JD. Structure-based identification of a ricin inhibitor. J Mol Biol 1997;266:1043-1049.
136. Birdsall DL, Finer-Moore J, Stroud RM. Entropy in bi-substrate enzymes: Proposed role of an alternate site in chaperoning substrate into, and products out of, thymidylate synthase. J Mol Biol 1996;255:522-535.
137. Matter H, Kotsonis P, Klingler O, Strobel H, Fröhlich LG, Frey A, Pfleiderer W, Schmidt HHHW. Structural requirements for inhibition of the neuronal nitric oxide synthase (NOS-I): 3D-QSAR analysis of 4-oxo- and 4-amino-pteridine-based inhibitors. J Med Chem 2002;45:2923-2941.
138. Cramer RD, Patterson DE, Bunce JE. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959-5967.
139. Clark M, Cramer RD, Jones DM, Patterson DE, Simeroth PE. Comparative molecular field analysis (CoMFA). 2. Towards its use with 3D-structural databases. Tetrahedron Comp Meth 1990;3:47-59.
140. Kubinyi H. 3D-QSAR in drug design. In: Theory, methods, and applications. Leiden: Escom; 1993.
141. Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130-4146.
142. Wold S, Albano C, Dunn WJ, Edlund U, Esbenson K, Geladi P, Hellberg S, Lindberg W, Sjöström M. Multivariate data analysis in chemistry. In: Kowalski B, editor. Chemometrics: Mathematics and statistics in chemistry. Dortrecht: Reidel; 1984. pp 17-95.
143. Dunn WJ, Wold S, Edlund U, Hellberg S, Gasteiger J. Multivariate structure-activity relationship between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method. Quant Struct Act Relat 1984;3:131-137.
144. Wold S. Cross-validatory estimation of the number of component in factor and principal component models. Technometrics 1978;4:397-405.
145. Cramer RD, Bunce JD, Patterson DE. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 1988;7:18-25.
146. Fedorov R, et al. (Manuscript in preparation).
147. Blundell TL, Carney DP, Gardner S, Hayes FRF, Howlin B, Hubbard TJP, Overington JP, Singh DA, Sibanda BL, Sutcliffe MJ. Knowledge-based protein modelling and design. Eur J Biochem 1988;172:513-520.
148. Sutcliffe MJ, Haneef I, Carney DP, Blundell TL. Knowledge-based modelling of homologous proteins. Part I: Three-dimensional frameworks derived from the simultaneous superposition of multiple structures. Protein Eng 1987;1:377-384.
149. Sutcliffe MJ, Hayes FRF, Blundell TL. Knowledge based modeling of homologous proteins. Part II: Rules for the conformations of substituted side chains. Protein Eng 1987;1:385-392.
150. Kastenholz MA, Pastor M, Cruciani G, Haaksma EEJ, Fox T. GRID/CPCA: A new computational tool to design selective ligands. J Med Chem 2000;43:3033-3044.
151. Goodford PJA. Computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985;28:849-857.
152. Boobbyer DNA, Goodford PJ, McWhinnie PM, Wade RC. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem 1989;32:1083-1094.
153. Westerhuis JA, Kourti T, Macgregor JF. Analysis of multiblock and hierarchical PCA and PLS models. J Chemom 1998;12:301-321.